NCT07042594

Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants

A Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Suzhou Ribo Life Science Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a Randomized, Single-blind, Placebo-Controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of Subcutaneously Administered RBD1119 in Healthy Participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	RBD1119	Subcutaneously Administered RBD1119 in Healthy Subjects.
DRUG	Placebo	Subcutaneously Administered Placebo in Healthy Subject.

Timeline

• Start date: 2025-08-26
• Primary completion: 2026-06-01
• Completion: 2026-09-01
• First posted: 2025-06-29
• Last updated: 2025-12-11

Locations

1 site across 1 country: Australia